Orgenesis Inc (ORGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Orgenesis Inc (ORGS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH397449D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Orgenesis Inc (Orgenesis) is a biopharmaceutical company that focuses on the development and manufacturing of regenerative cellular therapy and medicine for the treatment of insulin-dependent diabetes patients. The company, through its subsidiaries, offers contract development and manufacturing, and proprietary cell therapy development. It also provides GMP manufacturing, process development, quality management and assay development, and other services. Orgenesis offers cell therapies for autoimmune, oncologic, neurologic and orthopedic diseases. The company utilizes its proprietary technology to reprogram human liver cells into glucose-responsive insulin-producing cells to provide a practical cure for insulin-dependent diabetes. Orgenesis is headquartered in Germantown, Maryland, the US.

Orgenesis Inc (ORGS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Orgenesis Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Orgenesis Raises USD1.2 Million in Venture Financing 12

Orgenesis Raises USD5.3 Million in Financing Round 13

Partnerships 14

Zelluna Immunotherapy Enters into Partnership with Masthercell 14

CRISPR Therapeutics Enters into Agreement with MaSTherCell 15

Les Laboratoires Servier and Masthercell Enter into Agreement 16

Orgenesis Forms Joint Venture with Atvio Biotech 17

Orgenesis Forms Joint Venture with CureCell 18

Orgenesis Enters into Agreement with Biosequel 19

Orgenesis Enters into Research Agreement with GSRAC 20

Masthercell Forms Joint Venture with Kalon 21

Licensing Agreements 22

Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22

Orgenesis Enters into Licensing Agreement with Immugenyx 23

HekaBio Enters into Licensing Agreement with Orgenesis 24

Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25

Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26

Equity Offering 27

Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27

Masthercell Raises USD5.9 Million in Equity Financing 28

Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29

Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30

Orgenesis Raises Funds through Private Placement of Shares and Warrants 31

Orgenesis Raises Funds through Private Placement of Shares and Warrants 32

Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33

Orgenesis Announces Private Placement Of Shares For USD 3 Million 34

Orgenesis Completes Private Placement Of Units For USD 1.3 Million 35

Acquisition 36

Orgenesis Acquires MaSTherCell 36

Orgenesis Inc-Key Competitors 37

Orgenesis Inc-Key Employees 38

Orgenesis Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Apr 19, 2018: Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018 40

Government and Public Interest 42

Feb 13, 2017: Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program 42

Other Significant Developments 43

Mar 08, 2017: Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Orgenesis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Orgenesis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Orgenesis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Orgenesis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Orgenesis Raises USD1.2 Million in Venture Financing 12

Orgenesis Raises USD5.3 Million in Financing Round 13

Zelluna Immunotherapy Enters into Partnership with Masthercell 14

CRISPR Therapeutics Enters into Agreement with MaSTherCell 15

Les Laboratoires Servier and Masthercell Enter into Agreement 16

Orgenesis Forms Joint Venture with Atvio Biotech 17

Orgenesis Forms Joint Venture with CureCell 18

Orgenesis Enters into Agreement with Biosequel 19

Orgenesis Enters into Research Agreement with GSRAC 20

Masthercell Forms Joint Venture with Kalon 21

Orgenesis Enters into Licensing Agreement with Hemogenyx-Cell 22

Orgenesis Enters into Licensing Agreement with Immugenyx 23

HekaBio Enters into Licensing Agreement with Orgenesis 24

Orgenesis Enters into Licensing Agreement with BGN Technologies and National Institute for Biotechnology in the Negev 25

Orgenesis Enters Into Licensing Agreement With Tel Hashomer Medical Research For Autologous Insulin Producing Cells Regeneration Technology 26

Orgenesis Plans to Raise up to USD100 Million in Public Offering of Securities 27

Masthercell Raises USD5.9 Million in Equity Financing 28

Orgenesis Raises USD1 Million in Private Placement of Shares and Warrants 29

Orgenesis Raises USD4.3 Million in Private Placement of Shares and Warrants 30

Orgenesis Raises Funds through Private Placement of Shares and Warrants 31

Orgenesis Raises Funds through Private Placement of Shares and Warrants 32

Orgenesis Raises USD0.2 Million in Private Placement of Shares and Warrants 33

Orgenesis Announces Private Placement Of Shares For USD 3 Million 34

Orgenesis Completes Private Placement Of Units For USD 1.3 Million 35

Orgenesis Acquires MaSTherCell 36

Orgenesis Inc, Key Competitors 37

Orgenesis Inc, Key Employees 38

Orgenesis Inc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Orgenesis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17833
Site License
USD 500 INR 35665
Corporate User License
USD 750 INR 53498

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com